{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:07:17Z","timestamp":1789373237509,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/pcan.2012.13","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T11:24:49Z","timestamp":1335871489000},"page":"303-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial"],"prefix":"10.1038","volume":"15","author":[{"given":"P-L","family":"Kellokumpu-Lehtinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hj\u00e4lm-Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Thellenberg-Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"\u00c5str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Franzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Marttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Seke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Taalikka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ginman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the SPCG-13","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"key":"BFpcan201213_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/jnci\/djq154","volume":"102","author":"P Stattin","year":"2010","unstructured":"Stattin P, Holmberg E, Johansson J-E, Holmberg L, Adolfsson J, Hogosson J . Outcomes in localized prostate cancer: National prostate cancer register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 950\u2013958.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201213_CR2","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/jnci\/90.10.766","volume":"90","author":"MW Kattan","year":"1998","unstructured":"Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. Natl Cancer Inst 1998; 90: 766\u2013771.","journal-title":"Natl Cancer Inst"},{"key":"BFpcan201213_CR3","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1200\/JCO.2002.12.019","volume":"20","author":"M Graefen","year":"2002","unstructured":"Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002; 20: 3206\u20133612.","journal-title":"J Clin Oncol"},{"key":"BFpcan201213_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0090-4295(01)00978-5","volume":"57","author":"WW Roberts","year":"2001","unstructured":"Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57: 1033\u20131037.","journal-title":"Urology"},{"key":"BFpcan201213_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969\u2013974.","journal-title":"JAMA"},{"key":"BFpcan201213_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/MOU.0b013e3283384101","volume":"20","author":"R Grupp","year":"2010","unstructured":"Grupp R, Kibel A . High-risk localized prostate cancer: role of radical prostatectomy. Curr Opin Urol 2010; 20: 204\u20132106.","journal-title":"Curr Opin Urol"},{"key":"BFpcan201213_CR7","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1097\/01.ju.0000046241.95508.15","volume":"169","author":"B Akduman","year":"2003","unstructured":"Akduman B, Crawford D . The management of high risk prostate cancer. J Urol 2003; 169: 1993\u20131998.","journal-title":"J Urol"},{"key":"BFpcan201213_CR8","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jama.281.17.1598","volume":"281","author":"WU Shipley","year":"1999","unstructured":"Shipley WU, Thames HD, Sandler HM, Hanks GE, Zeitman AL, Perez C et al. Radiotherapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281: 1598\u20131604.","journal-title":"JAMA"},{"key":"BFpcan201213_CR9","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1200\/JCO.2000.18.23.3904","volume":"23","author":"A Pollack","year":"2000","unstructured":"Pollack A, Zagars GK, Smith LG, Lee JJ, vonEschenbach AL, Antolak JA et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70\u2009Gy with 78\u2009Gy for prostate cancer. J Clin Oncol 2000; 23: 3904\u20133911.","journal-title":"J Clin Oncol"},{"key":"BFpcan201213_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer. Recommendations of RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965\u2013974.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFpcan201213_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semradonc.2005.08.003","volume":"16","author":"LK Lee","year":"2006","unstructured":"Lee LK . Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 2006; 16: 20\u201328.","journal-title":"Semin Radiat Oncol"},{"key":"BFpcan201213_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2005.06.005","volume":"76","author":"CJ Tyrrell","year":"2005","unstructured":"Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P et al. On the behalf of the \u2018Casodex\u2019 early prostate cancer trialist gourp. Bicalutamide (\u2018Casodex\u2019) 150\u2009mg as adjuvant to radiotherapy in patients with localized or locally advanced prostate cancer: Results of a randomized study. Radiother Oncol 2005; 76: 4\u201310.","journal-title":"Radiother Oncol"},{"key":"BFpcan201213_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M, Colette L, Blank L, Walde P, Dubois JB, Mirimano RO et al. Long-term results with androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). Lancet 2002; 360: 103\u2013108.","journal-title":"Lancet"},{"key":"BFpcan201213_CR14","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","volume":"21","author":"GE Hanks","year":"2003","unstructured":"Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972\u20133978.","journal-title":"J Clin Oncol"},{"key":"BFpcan201213_CR15","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.24392","volume":"115","author":"E Bria","year":"2009","unstructured":"Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri E, Sperduti I et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer. Meta-analysis of randomized trials. Cancer 2009; 115: 3446\u20133456.","journal-title":"Cancer"},{"key":"BFpcan201213_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/1471-2407-10-675","volume":"10","author":"F Cuppone","year":"2010","unstructured":"Cuppone F, Bria E, Giannarelli D, Vaccaro D, Milella M, Nistico C et al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer 2010; 10: 675, 8 pages.","journal-title":"BMC Cancer"},{"key":"BFpcan201213_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","volume":"6","author":"JW Denham","year":"2005","unstructured":"Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841\u2013850.","journal-title":"Lancet Oncol"},{"key":"BFpcan201213_CR18","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513\u20131520.","journal-title":"N Engl J Med"},{"key":"BFpcan201213_CR19","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"I Tannock","year":"2004","unstructured":"Tannock I, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502\u20131512.","journal-title":"N Engl J Med"},{"key":"BFpcan201213_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1517\/14728214.8.2.291","volume":"8","author":"JA Eastham","year":"2003","unstructured":"Eastham JA . High-risk localized prostate cancer. Multimodal treatment strategies combining neoadjuvant hormonal therapy and\/or chemotherapy with radical prostatectomy. Expert Opin Emerg Drugs 2003; 8: 291\u2013295.","journal-title":"Expert Opin Emerg Drugs"},{"key":"BFpcan201213_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.urology.2003.09.052","volume":"62","author":"JA Eastham","year":"2003","unstructured":"Eastham JA, Kelly WK, Grossfeld GD, Small EJ . Cancer and Leukemia Group B (CALGB) 90203: a randomised phase III study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003; 62: 55\u201362.","journal-title":"Urology"},{"key":"BFpcan201213_CR22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.urology.2004.01.040","volume":"63","author":"R Dreicer","year":"2004","unstructured":"Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J et al. Phase II Trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138\u20131142.","journal-title":"Urology"},{"key":"BFpcan201213_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ijrobp.2010.06.042","volume":"81","author":"SJ DiBiase","year":"2011","unstructured":"DiBiase SJ, Hussain A, Kataria R, Amin P, Bassi S, Dawson N et al. Long-term results of a prospective phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. I. J Radiat Oncol Biol Phys 2011; 81: 731\u2013736.","journal-title":"J Radiat Oncol Biol Phys"},{"key":"BFpcan201213_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa053028","volume":"23","author":"H Joensuu","year":"2006","unstructured":"Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R et al Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 23: 809\u2013812.","journal-title":"N Engl J Med"},{"key":"BFpcan201213_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2011.35.4639","volume":"30","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R et al. Adjuvant capecitabine, docetaxel, cyclophosphamide and epirubicin for early breast cancer: Final Analysis of a Randomized Trial (FinXX). J Clin Oncol 2012; 30: 11\u201318.","journal-title":"J Clin Oncol"},{"key":"BFpcan201213_CR26","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.ejca.2010.04.031","volume":"46","author":"C Falandry","year":"2010","unstructured":"Falandry C, Campone M, Cartron G, Guerin D, Freyer G . Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer 2010; 46: 2389\u20132398.","journal-title":"Eur J Cancer"},{"key":"BFpcan201213_CR27","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2007.15.1928","volume":"26","author":"D Rathkopf","year":"2008","unstructured":"Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R et al. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastarate prostate cancer. J Clin Oncol 2008; 26: 2959\u20132965.","journal-title":"J Clin Oncol"},{"key":"BFpcan201213_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijrobp.2008.05.020","volume":"73","author":"SA Rosenthal","year":"2009","unstructured":"Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99.-02. Int J Radiat Oncol Biol Phys 2009; 73: 672\u2013678.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFpcan201213_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdp554","volume":"12","author":"C Heyns","year":"2010","unstructured":"Heyns C . Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy. Ann Oncol 2010; 12: 903\u2013904.","journal-title":"Ann Oncol"},{"key":"BFpcan201213_CR30","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.juro.2010.02.013","volume":"183","author":"G Huang","year":"2010","unstructured":"Huang G, Sadetsky N, Penson D . Health related quality of life for men treated for localized prostate cancer with long-term follow up. J Urol 2010; 183: 2206\u20132212.","journal-title":"J Urol"},{"key":"BFpcan201213_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"N Keating","year":"2010","unstructured":"Keating N, O\u2019Malley J, Freedland J, Smith R . Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201213_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijrobp.2008.10.082","volume":"75","author":"AV D\u2019Amico","year":"2009","unstructured":"D\u2019Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW . Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys 2009; 75: 10\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFpcan201213_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/CCO.0b013e3283378c84","volume":"22","author":"Y Kwok","year":"2010","unstructured":"Kwok Y, Yovino S . Update on radiation-based therapies for prostate cancer. Curr Opin Oncol 2010; 22: 257\u2013262.","journal-title":"Curr Opin Oncol"},{"key":"BFpcan201213_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MOU.0b013e32833817aa","volume":"20","author":"K Stephans","year":"2010","unstructured":"Stephans K, Xia P, Tendulkar R, Ciezki J . The Current status of image-guided external beam radiotherapy for prostate cancer. Curr Opin Urol 2010; 20: 223\u2013228.","journal-title":"Curr Opin Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201213","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:24:56Z","timestamp":1648675496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFpcan201213"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2012.13","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,1]]},"assertion":[{"value":"23 December 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial is supported by Sanofi-Aventis. Dr Kellokumpu-Lehtinen and Dr Marttila has received compensation for an advisory role or lectures from Sanofi-Aventis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}